LU92517I2 - Delamanide et ses dérivés pharmaceutiquement acceptables - Google Patents

Delamanide et ses dérivés pharmaceutiquement acceptables

Info

Publication number
LU92517I2
LU92517I2 LU92517C LU92517C LU92517I2 LU 92517 I2 LU92517 I2 LU 92517I2 LU 92517 C LU92517 C LU 92517C LU 92517 C LU92517 C LU 92517C LU 92517 I2 LU92517 I2 LU 92517I2
Authority
LU
Luxembourg
Prior art keywords
delamanide
pharmaceutically acceptable
acceptable derivatives
derivatives
pharmaceutically
Prior art date
Application number
LU92517C
Other languages
English (en)
French (fr)
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of LU92517I2 publication Critical patent/LU92517I2/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
LU92517C 2002-10-11 2014-08-13 Delamanide et ses dérivés pharmaceutiquement acceptables LU92517I2 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2002298259 2002-10-11

Publications (1)

Publication Number Publication Date
LU92517I2 true LU92517I2 (fr) 2014-10-13

Family

ID=32089299

Family Applications (1)

Application Number Title Priority Date Filing Date
LU92517C LU92517I2 (fr) 2002-10-11 2014-08-13 Delamanide et ses dérivés pharmaceutiquement acceptables

Country Status (26)

Country Link
US (1) US7262212B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (2) EP2570418A3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP4186065B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR100723847B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (4) CN102532162B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AR (4) AR041198A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU2003272979B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BE (1) BE2014C053I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BRPI0314344B8 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2497569C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CY (2) CY1113578T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK1555267T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2400179T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR (1) FR14C0066I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HUS1400046I1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
LU (1) LU92517I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MXPA05003674A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MY (1) MY139244A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (3) PL217919B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (1) PT1555267E (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RU (1) RU2326121C3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SI (1) SI1555267T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW (1) TWI347946B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
UA (1) UA83200C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2004033463A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA200501033B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002036587A2 (en) 2000-11-01 2002-05-10 Cor Therapeutics, Inc. Process for the production of 4-quinazolinylpiperazin-1-carboxylic acid phenylamides
KR100655670B1 (ko) * 2002-10-15 2007-02-28 오쓰까 세이야꾸 가부시키가이샤 1-치환된 4-니트로이미다졸 화합물 및 이의 제조 방법
RU2365593C2 (ru) 2003-10-31 2009-08-27 Оцука Фармасьютикал Ко., Лтд. ПРОИЗВОДНЫЕ 2,3-ДИГИДРО-6-НИТРОИМИДАЗО [2,1-b] ОКСАЗОЛА ДЛЯ ЛЕЧЕНИЯ ТУБЕРКУЛЕЗА
JP4761756B2 (ja) * 2003-10-31 2011-08-31 大塚製薬株式会社 ２，３−ジヒドロイミダゾ［２，１−ｂ］オキサゾ−ル化合物
TWI300409B (en) 2004-02-18 2008-09-01 Otsuka Pharma Co Ltd Method for producing 4-nitroimidazole compound
CN1938292B (zh) 2004-03-31 2011-10-05 日本曹达株式会社 环胺化合物和有害生物防除剂
JP4787529B2 (ja) * 2004-04-09 2011-10-05 大塚製薬株式会社 医薬組成物
JP4789966B2 (ja) * 2004-04-09 2011-10-12 大塚製薬株式会社 医薬組成物
ES2337728T3 (es) * 2005-06-20 2010-04-28 Schering Corporation Piperidinas sustituidas unidas a carbono y sus derivados utiles como antagonistas de histamina h3.
PT1906926E (pt) * 2005-07-28 2011-01-26 Otsuka Pharma Co Ltd Composição farmacêutica que contém derivados de 2,3-di-hidro-6-nitroimidazo[2,1-b]oxazole
TWI368509B (en) * 2005-10-05 2012-07-21 Otsuka Pharma Co Ltd Antituberculous therapeutic drugs and kit containing the same
JP5105818B2 (ja) * 2005-10-05 2012-12-26 大塚製薬株式会社 医薬組成物
US8338607B2 (en) 2005-10-06 2012-12-25 Nippon Soda Co., Ltd. Cyclic amine compounds and agents for pest control
TW200800268A (en) * 2005-11-04 2008-01-01 Otsuka Pharma Co Ltd Medicinal composition showing improved drug absorbability
EP1968961A2 (en) * 2005-12-21 2008-09-17 Decode Genetics EHF Biaryl nitrogen heterocycle inhibitors of lta4h for treating inflammation
EP1986637A1 (en) * 2006-02-13 2008-11-05 Laboratoires Serono SA Sulfonamide derivatives for the treatment of bacterial infections
JP2007297305A (ja) * 2006-04-28 2007-11-15 Daiso Co Ltd Ｎ−（２，３−エポキシ−２−メチルプロピル）フタルイミドの製造法
CA2678577A1 (en) * 2007-02-26 2008-09-04 Vitae Pharmaceuticals, Inc. Cyclic urea and carbamate inhibitors of 11.beta.-hydroxysteroid dehydrogenase 1
AR070301A1 (es) 2007-05-08 2010-03-31 Otsuka Pharma Co Ltd Compuesto epoxi y metodo para producir el mismo
JP5470557B2 (ja) * 2007-07-26 2014-04-16 ヴァイティー ファーマシューティカルズ，インコーポレイテッド １１β−ヒドロキシステロイドデヒドロゲナーゼ１型の阻害剤の合成
PE20090595A1 (es) * 2007-08-15 2009-06-06 Glaxo Group Ltd Derivados de quinoliniloxipiperidina y pirrolidina como antagonistas del receptor h1
JP2011500634A (ja) * 2007-10-16 2011-01-06 グラクソ グループ リミテッド 炎症性疾患およびアレルギー性疾患の治療に用いるキノリン誘導体
AR069207A1 (es) * 2007-11-07 2010-01-06 Vitae Pharmaceuticals Inc Ureas ciclicas como inhibidores de la 11 beta - hidroxi-esteroide deshidrogenasa 1
US8440658B2 (en) 2007-12-11 2013-05-14 Vitae Pharmaceuticals, Inc. Cyclic urea inhibitors of 11β-hydroxysteroid dehydrogenase 1
TW200934490A (en) * 2008-01-07 2009-08-16 Vitae Pharmaceuticals Inc Lactam inhibitors of 11 &abgr;-hydroxysteroid dehydrogenase 1
WO2009094169A1 (en) 2008-01-24 2009-07-30 Vitae Pharmaceuticals, Inc. Cyclic carbazate and semicarbazide inhibitors of 11beta-hydroxysteroid dehydrogenase 1
JP5734666B2 (ja) * 2008-02-11 2015-06-17 ヴァイティー ファーマシューティカルズ，インコーポレイテッド １１β−ヒドロキシステロイドデヒドロゲナーゼ１の１，３−オキサアゼパン−２−オン及び１，３−ジアゼパン−２−オン阻害剤
JP5730021B2 (ja) * 2008-02-15 2015-06-03 ヴァイティー ファーマシューティカルズ，インコーポレイテッド １１β−ヒドロキシステロイドデヒドロゲナーゼ１の阻害剤としてのシクロアルキルラクタム誘導体
US20110105504A1 (en) * 2008-03-18 2011-05-05 Vitae Pharmaceuticals ,Inc. Inhibitors Of 11beta-Hydroxysteroid Dehydrogenase Type 1
WO2009120789A1 (en) * 2008-03-26 2009-10-01 Global Alliance For Tb Drug Development Bicyclic nitroimidazoles covalently linked to substituted phenyl oxazolidinones
CL2009001058A1 (es) 2008-05-01 2010-09-10 Vitae Pharmaceuticals Inc Compuestos derivados de oxazinas sustituidas, inhibidores de la 11b-hidroxiesteroide deshidrogenasa de tipo-1; composicion farmaceutica; y uso del compuesto para inhibir la actividad de 11b-hsd1, como en el tratamiento de la diabetes, dislipidemia, hipertension, obesidad, cancer, glaucoma, entre otras.
WO2009134384A1 (en) * 2008-05-01 2009-11-05 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
EP2300461B1 (en) * 2008-05-01 2013-04-17 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
WO2009134387A1 (en) 2008-05-01 2009-11-05 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
KR20110050459A (ko) 2008-07-25 2011-05-13 비타이 파마슈티컬즈, 인코포레이티드 11베타-하이드록시스테로이드 탈수소효소 1의 고리형 억제제
CA2729998A1 (en) 2008-07-25 2010-01-28 Boehringer Ingelheim International Gmbh Inhibitors of 11beta-hydroxysteroid dehydrogenase 1
US9643922B2 (en) 2008-08-18 2017-05-09 Yale University MIF modulators
US9540322B2 (en) 2008-08-18 2017-01-10 Yale University MIF modulators
CN102186833A (zh) * 2008-08-18 2011-09-14 耶鲁大学 Mif调节剂
US8558005B2 (en) 2008-08-21 2013-10-15 Dynamit Nobel Gmbh Explosivstoff-Und Systemtechnik Methods for the production of 2-halo-4-nitroimidazole and intermediates thereof
WO2010143007A1 (en) * 2009-06-10 2010-12-16 Dynamit Nobel Gmbh Explosivstoff-Und Systemtechnik Method for the production of 2-halogeno-4-nitroimidazole
US8637505B2 (en) 2009-02-04 2014-01-28 Boehringer Ingelheim International Gmbh Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
TW201039034A (en) * 2009-04-27 2010-11-01 Chunghwa Picture Tubes Ltd Pixel structure and the method of forming the same
KR20120061771A (ko) * 2009-04-30 2012-06-13 비타이 파마슈티컬즈, 인코포레이티드 11베타-하이드록시스테로이드 탈수소효소 1의 고리형 억제제
MA33216B1 (fr) 2009-04-30 2012-04-02 Boehringer Ingelheim Int Inhibiteurs cycliques de la 11béta-hydroxysteroïde déshydrogénase 1
EP2440537A1 (en) 2009-06-11 2012-04-18 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 based on the 1,3 -oxazinan- 2 -one structure
JP5749263B2 (ja) 2009-07-01 2015-07-15 ヴァイティー ファーマシューティカルズ，インコーポレイテッド １１β−ヒドロキシステロイドデヒドロゲナーゼ１の環状インヒビター
EP2459570B1 (en) * 2009-07-31 2014-12-24 Global Alliance For Tb Drug Development Nitroimidazooxazine analogues and their uses
KR101746482B1 (ko) * 2009-07-31 2017-06-27 글로벌 알리앙스 포 티비 드럭 디벨롭먼트 니트로이미다조옥사진 및 항결핵 치료요법에서의 이의 용도
US9198913B2 (en) 2009-07-31 2015-12-01 Global Alliance For Tb Drug Development Nitroimidazooxazines and their uses in anti-tubercular therapy
EP2495563A4 (en) 2009-10-26 2013-04-10 Fujifilm Ri Pharma Co Ltd DIAGNOSTIC AGENT FOR INFECTIOUS DISEASES
TW201200523A (en) * 2010-01-29 2012-01-01 Otsuka Pharma Co Ltd Synthetic intermediate of oxazole compound and method for producing the same
GB201012209D0 (en) * 2010-05-31 2010-09-08 Ge Healthcare Ltd In vivo imaging agent
EP2582698B1 (en) 2010-06-16 2016-09-14 Vitae Pharmaceuticals, Inc. Substituted 5-,6- and 7-membered heterocycles, medicaments containing such compounds, and their use
JP5813106B2 (ja) 2010-06-25 2015-11-17 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 代謝障害の処置のための１１−β−ＨＳＤ１のインヒビターとしてのアザスピロヘキサノン
AU2011325286B2 (en) 2010-11-02 2015-04-16 Boehringer Ingelheim International Gmbh Pharmaceutical combinations for the treatment of metabolic disorders
US9051333B2 (en) 2011-04-15 2015-06-09 Otsuka Pharmaceutical Co., Ltd. 6,7-dihydroimidazo [2,1-b] [1,3]oxazine bactericides
JP2015006994A (ja) * 2011-10-28 2015-01-15 大正製薬株式会社 ジヒドロイミダゾオキサゾール誘導体
WO2014014845A1 (en) 2012-07-18 2014-01-23 Vertex Pharmaceuticals Incorporated Combination therapy comprising|1 -ethyl-3-[5-[2-{1 -hydroxy-1 -methyl-ethyl}pyrimidin-5-yl]-7-(tetra hydrofuran-2-|yl}-1 h-benzimidazol-2-yl]urea and derivatives thereof to treat mycobacterium|diseases
FR3000064A1 (fr) 2012-12-21 2014-06-27 Univ Lille Ii Droit & Sante Composes de type spiroisoxazoline ayant une activite potentialisatrice de l'activite d'un antibiotique-composition et produit pharmaceutiques comprenant de tels composes
EP3052503B1 (en) * 2013-10-04 2018-10-24 Council of Scientific & Industrial Research 6-nitro-2,3-dihydroimidazo[2,1-b]oxazoles and a process for the preparation thereof
CN103524492A (zh) * 2013-10-23 2014-01-22 中国药科大学 侧链含硝基咪唑基团取代的喹诺酮类化合物、其制备及用途
TWI687409B (zh) 2014-08-28 2020-03-11 日商大塚製藥股份有限公司 稠合雜環化合物
WO2016063298A1 (en) * 2014-10-21 2016-04-28 Council Of Scientific & Industrial Research Substituted 1,2,3-triazol-1-yl-methyl-2,3-dihydro-2-methyl-6-nitroimidazo[2,1-b]oxazoles as anti-mycobacterial agents and a process for the preparation thereof
CN105732659B (zh) * 2014-12-12 2019-07-16 上海阳帆医药科技有限公司 硝基咪唑类化合物及其制备方法和在制药中的用途
MX2017009810A (es) * 2015-01-29 2018-11-09 Medshine Discovery Inc Derivado de nitroimidazol contra tuberculosis pulmonar.
EP3275862B1 (en) 2015-03-27 2020-08-12 Otsuka Pharmaceutical Co., Ltd. Method for producing 1-(4-hydroxyphenyl)-4-(4-trifluoromethoxyphenoxy)piperidine or salt thereof
CN106317072B (zh) * 2015-06-17 2020-03-17 盟科医药技术(上海)有限公司 用于分枝杆菌感染治疗的杂环化合物及其应用
EP3421454B9 (en) 2016-02-26 2023-08-09 Otsuka Pharmaceutical Co., Ltd. Piperidine derivative
CN105859628B (zh) * 2016-04-19 2018-08-07 清远职业技术学院 一种抗菌化合物对n咪唑苯甲醛缩邻甲苯胺希夫碱及其制备方法和应用
CN109496214B (zh) * 2016-07-22 2024-09-10 成都嘉葆药银医药科技有限公司 一种硝基咪唑类化合物的晶型、盐型及其制备方法
CA3072838A1 (en) * 2017-08-16 2019-02-21 Glaxosmithkline Intellectual Property Development Limited Novel compounds
US20210251902A1 (en) 2018-06-11 2021-08-19 Otsuka Pharmaceutical Co., Ltd. Delamanid-containing composition
CN109705022A (zh) * 2018-12-28 2019-05-03 上海彩迩文生化科技有限公司 一种芳香胺中间体的制备方法
CN112300192B (zh) * 2019-08-02 2023-08-11 南京长澳医药科技有限公司 硝基咪唑类化合物及其制备方法和用途
CN110483549B (zh) * 2019-08-30 2021-03-05 沈阳药科大学 一种硝基咪唑吡喃类抗结核药物的制备方法
CN110615800A (zh) * 2019-10-16 2019-12-27 李丽丽 硝基咪唑类化合物及其制备方法和用途
CN112156088B (zh) * 2020-10-30 2021-08-31 健民药业集团股份有限公司 一种化合物在制备结核分枝杆菌抑制剂中的用途
CN113603706A (zh) * 2021-08-04 2021-11-05 深圳市泰力生物医药有限公司 德拉马尼的晶型、含有该晶型的活性药物和药物组合物
JPWO2024024938A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2022-07-29 2024-02-01
CN115368252B (zh) * 2022-09-19 2024-01-12 西北农林科技大学 一种4-胺基酚类衍生物及应用
CN116640106B (zh) * 2023-05-11 2024-03-08 郑州大学 一种苯基哌嗪类化合物及其制备方法、应用
CN119059990B (zh) * 2024-11-01 2025-02-07 安徽昊帆生物有限公司 1-氨基甲酸叔丁酯哌嗪的制备方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5668127A (en) 1995-06-26 1997-09-16 Pathogenesis Corporation Nitroimidazole antibacterial compounds and methods of use thereof

Also Published As

Publication number Publication date
CN102532162A (zh) 2012-07-04
AR091771A2 (es) 2015-02-25
PL217919B1 (pl) 2014-09-30
ZA200501033B (en) 2006-06-28
CA2497569C (en) 2011-05-24
BE2014C053I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2022-08-30
CY1113578T1 (el) 2016-06-22
EP1555267B1 (en) 2013-01-16
AU2003272979B2 (en) 2009-07-23
CY2014041I1 (el) 2016-07-27
PT1555267E (pt) 2013-01-29
BR0314344A (pt) 2005-07-12
AR041198A1 (es) 2005-05-04
US20060094767A1 (en) 2006-05-04
TW200420568A (en) 2004-10-16
UA83200C2 (en) 2008-06-25
RU2326121C2 (ru) 2008-06-10
CN102532162B (zh) 2015-05-27
KR100723847B1 (ko) 2007-05-31
ES2400179T3 (es) 2013-04-08
CA2497569A1 (en) 2004-04-22
CN1705670A (zh) 2005-12-07
PL404913A1 (pl) 2013-09-30
AR089950A2 (es) 2014-10-01
FR14C0066I1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2014-10-17
CN100366624C (zh) 2008-02-06
HUS1400046I1 (hu) 2017-04-28
TWI347946B (en) 2011-09-01
BRPI0314344B8 (pt) 2021-05-25
EP1555267A1 (en) 2005-07-20
EP1555267A4 (en) 2010-08-18
EP2570418A2 (en) 2013-03-20
US7262212B2 (en) 2007-08-28
FR14C0066I2 (fr) 2015-05-22
CN101255170A (zh) 2008-09-03
BRPI0314344B1 (pt) 2019-11-26
MY139244A (en) 2009-09-30
SI1555267T1 (sl) 2013-05-31
AR086485A2 (es) 2013-12-18
MXPA05003674A (es) 2005-06-08
DK1555267T3 (da) 2013-02-11
AU2003272979A1 (en) 2004-05-04
HK1085463A1 (zh) 2006-08-25
RU2326121C3 (ru) 2021-09-17
PL409525A1 (pl) 2014-11-10
JP4186065B2 (ja) 2008-11-26
PL376157A1 (en) 2005-12-27
EP2570418A3 (en) 2013-07-03
HK1171018A1 (en) 2013-03-15
CY2014041I2 (el) 2016-07-27
WO2004033463A1 (ja) 2004-04-22
JP2004149527A (ja) 2004-05-27
CN101172981A (zh) 2008-05-07
KR20050061473A (ko) 2005-06-22
RU2005114017A (ru) 2006-01-20

Similar Documents

Publication Publication Date Title
LU92517I2 (fr) Delamanide et ses dérivés pharmaceutiquement acceptables
LU92513I2 (fr) Sofosbuvir et ses dérivés pharmaceutiquement acceptables (solvaldi)
LU92419I2 (fr) Riociguat et ses dérivés pharmaceutiquement acceptables (ADEMPAS®)
LU92336I2 (fr) Trastuzumab emtansine et ses dérivés pharmaceutiquement acceptables (KADCYLA)
LU93093I2 (fr) Nécitumumab et ses dérivés pharmaceutiquement acceptables (portrazza)
LU92381I2 (fr) Macitentan et ses dérivés pharmaceutiquement acceptables (OPSUMIT)
LU92871I2 (fr) Fumarate de diméthyle et ses dérivés pharmaceutiquement acceptables (tecfidera)
LU93189I2 (fr) Ixekizumab et ses dérivés pharmaceutiquement acceptables (TALTZ)
LU92024I2 (fr) Pasireotide et ses dérivés pharmaceutiquement acceptables (SIGNIFOR)
LU91882I2 (fr) Pradofloxacin et ses dérivés pharmaceutiquement acceptables (VERAFLOX®)
LU91624I2 (fr) Canakinumab et ses dérivés pharmaceutiquement acceptables (ILARIS®)
LUC00127I1 (fr) Dacomitinib et ses derives pharmaceutiquement accepatbles ( vizimpro )
IS2599B (is) 3-fenýlsúlfónýl-8-píperasín-1-ýl-kínólín og lyfjafræðilega viðurkenndar afleiður þess
LU92326I2 (fr) Canakinumab et ses dérivés pharmaceutiquement acceptables (ILARIS)
LU91883I2 (fr) Pradofloxacin et ses dérivés pharmaceutiquement acceptables (VERAFLOX®)
LU92182I2 (fr) Dapagliflozine et ses sels pharmaceutiquement acceptables
LU91757I2 (fr) Denosumab et ses dérivés pharmaceutiquement acceptables (PROLIA®)
LU92745I2 (fr) Nétupitant/Palonosétron et leurs dérivés pharmaceutiquement acceptables (AKYNZEOr)
LU91269I2 (fr) Rotigotine et ses dérivés pharmaceutiquement acceptables (neupro)
LU92634I2 (fr) Flutémétamol (18f) et ses dérivés pharmaceutiquement acceptables (vizamyl)
DE60324099D1 (de) Arzneistoffhaltiger tampon
IS2504B (is) Fosfónóoxýkínasólínafleiður og lyfjafræileg notkun þeirra
IS7872A (is) Pýrrólópýrimidín afleiður
ATE478870T1 (de) Spiroindolinpiperidinderivate
ATE460418T1 (de) Heterocyclocarboxamidderivate